GLP-1 SEMA — 10 mg

GLP-1 SEMA refers here to semaglutide, not the unmodified endogenous GLP-1 hormone. Umbrella Labs identifies semaglutide as a Novo Nordisk-developed GLP-1 receptor agonist whose fatty-acid modification promotes albumin binding and prolonged circulation. The compound is associated with incretin signaling, appetite regulation and metabolic research. The vendor connects its research description with major studies of pharmaceutical semaglutide rather than reporting a clinical trial of its own lyophilized vial.

The STEP 1 trial studied adults with overweight or obesity without diabetes and reported substantially greater average weight reduction with semaglutide than placebo alongside lifestyle intervention. The SELECT trial addressed a different question: cardiovascular outcomes in people with established cardiovascular disease and overweight or obesity but no diabetes. Its investigators reported fewer cardiovascular deaths, nonfatal heart attacks or nonfatal strokes in the semaglutide group over the study follow-up. These findings explain the seller’s weight-management and cardiometabolic research themes. The population and preparation remain part of each finding: evidence involving a defined pharmaceutical trial product does not establish that every product carrying the SEMA abbreviation has identical composition or performance.